BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 20525462)

  • 1. [Risk of anastomotic leakage in postoperative treatment with non-steroidal anti-inflammatory drugs].
    Klein M; Gögenur I; Rosenberg J
    Ugeskr Laeger; 2010 May; 172(22):1660-2. PubMed ID: 20525462
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Postoperative non-steroidal anti-inflammatory drugs and colorectal anastomotic leakage. NSAIDs and anastomotic leakage.
    Klein M
    Dan Med J; 2012 Mar; 59(3):B4420. PubMed ID: 22381097
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclo-oxygenase 2 inhibitors and the risk of anastomotic leakage after fast-track colonic surgery.
    Holte K; Andersen J; Jakobsen DH; Kehlet H
    Br J Surg; 2009 Jun; 96(6):650-4. PubMed ID: 19434706
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of postoperative diclofenac on anastomotic healing, skin wounds and subcutaneous collagen accumulation: a randomized, blinded, placebo-controlled, experimental study.
    Klein M; Krarup PM; Kongsbak MB; Agren MS; Gögenur I; Jorgensen LN; Rosenberg J
    Eur Surg Res; 2012; 48(2):73-8. PubMed ID: 22343935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased risk of anastomotic leakage with diclofenac treatment after laparoscopic colorectal surgery.
    Klein M; Andersen LP; Harvald T; Rosenberg J; Gogenur I
    Dig Surg; 2009; 26(1):27-30. PubMed ID: 19153492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Simultaneous assessment of short-term gastrointestinal benefits and cardiovascular risks of selective cyclooxygenase 2 inhibitors and nonselective nonsteroidal antiinflammatory drugs: an instrumental variable analysis.
    Schneeweiss S; Solomon DH; Wang PS; Rassen J; Brookhart MA
    Arthritis Rheum; 2006 Nov; 54(11):3390-8. PubMed ID: 17075817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of diclofenac on cyclooxygenase-2 levels and early breaking strength of experimental colonic anastomoses and skin incisions.
    Klein M; Krarup PM; Burcharth J; Ågren MS; Gögenur I; Jorgensen LN; Rosenberg J
    Eur Surg Res; 2011; 46(1):26-31. PubMed ID: 21135559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction.
    Gislason GH; Jacobsen S; Rasmussen JN; Rasmussen S; Buch P; Friberg J; Schramm TK; Abildstrom SZ; Køber L; Madsen M; Torp-Pedersen C
    Circulation; 2006 Jun; 113(25):2906-13. PubMed ID: 16785336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of anastomotic leakage with non-steroidal anti-inflammatory drugs in colorectal surgery.
    Gorissen KJ; Benning D; Berghmans T; Snoeijs MG; Sosef MN; Hulsewe KW; Luyer MD
    Br J Surg; 2012 May; 99(5):721-7. PubMed ID: 22318712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative assessment of the gastrointestinal and cardiovascular risk-benefit of celecoxib compared to individual NSAIDs at the population level.
    Varas-Lorenzo C; Maguire A; Castellsague J; Perez-Gutthann S
    Pharmacoepidemiol Drug Saf; 2007 Apr; 16(4):366-76. PubMed ID: 16897817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease.
    Ray WA; Varas-Lorenzo C; Chung CP; Castellsague J; Murray KT; Stein CM; Daugherty JR; Arbogast PG; García-Rodríguez LA
    Circ Cardiovasc Qual Outcomes; 2009 May; 2(3):155-63. PubMed ID: 20031832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hospitalization for gastrointestinal bleeding associated with non-steroidal anti-inflammatory drugs among elderly patients using low-dose aspirin: a retrospective cohort study.
    Rahme E; Bardou M; Dasgupta K; Toubouti Y; Ghosn J; Barkun AN
    Rheumatology (Oxford); 2007 Feb; 46(2):265-72. PubMed ID: 16844699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular events associated with the use of four nonselective NSAIDs (etodolac, nabumetone, ibuprofen, or naproxen) versus a cyclooxygenase-2 inhibitor (celecoxib): a population-based analysis in Taiwanese adults.
    Huang WF; Hsiao FY; Wen YW; Tsai YW
    Clin Ther; 2006 Nov; 28(11):1827-36. PubMed ID: 17213003
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study.
    Singh G; Fort JG; Goldstein JL; Levy RA; Hanrahan PS; Bello AE; Andrade-Ortega L; Wallemark C; Agrawal NM; Eisen GM; Stenson WF; Triadafilopoulos G;
    Am J Med; 2006 Mar; 119(3):255-66. PubMed ID: 16490472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of cardiovascular events in patients receiving celecoxib: a meta-analysis of randomized clinical trials.
    White WB; West CR; Borer JS; Gorelick PB; Lavange L; Pan SX; Weiner E; Verburg KM
    Am J Cardiol; 2007 Jan; 99(1):91-8. PubMed ID: 17196469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Postoperative use of non-steroidal anti-inflammatory drugs in patients with anastomotic leakage requiring reoperation after colorectal resection: cohort study based on prospective data.
    Klein M; Gögenur I; Rosenberg J
    BMJ; 2012 Sep; 345():e6166. PubMed ID: 23015299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the baseline cardiovascular risk profile among hypertensive patients prescribed COX-2-specific inhibitors or nonspecific NSAIDs: data from real-life practice.
    Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC
    Am J Manag Care; 2002 Oct; 8(15 Suppl):S392-400. PubMed ID: 12416789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost of heart failure among hypertensive users of nonspecific NSAIDs and COX-2-specific inhibitors.
    Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC
    Am J Manag Care; 2002 Oct; 8(15 Suppl):S414-27. PubMed ID: 12416791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor.
    Goldstein JL; Silverstein FE; Agrawal NM; Hubbard RC; Kaiser J; Maurath CJ; Verburg KM; Geis GS
    Am J Gastroenterol; 2000 Jul; 95(7):1681-90. PubMed ID: 10925968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of gastrointestinal effects with COX-2 inhibitors and NSAIDs: study conclusions do not reflect findings for celecoxib.
    Feczko J
    BMJ; 2005 Dec; 331(7530):1473-4. PubMed ID: 16356991
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.